eli lilly and company retatrutide

Eli Lilly, Weight Loss

Eli Lilly's next-generation obesity drug secures first phase III win

Shares of Eli Lilly LLY rose nearly 2% on Thursday after the company announced that a late-stage study evaluating its experimental once-weekly weight-loss drug, retatrutide, met all primary and key secondary endpoints.

· 1d

Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug

· 2d

Eli Lilly: Retatrutide Justifies Hype With Best Weight Loss Data Yet - I'm Sold

· 1d

Exclusive-US FDA brass pushed internally for speedier Lilly weight-loss pill verdict

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli Lilly's experimental weight‑loss pill, after the company pushed for a faster ...

· 1d

Lilly's next-gen drug shows greater weight loss than Zepbound in late-stage trial

· 1d

Eli Lilly's next-gen obesity drug shows biggest weight loss yet in clinical trial

StockStory.org on MSN

Eli Lilly (LLY) Stock Is Up, What You Need To Know

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the morning session after the company announced highly positive Phase 3 trial results for its next-generation weight loss candidate,

BioSpace

Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called dysesthesia, has emerged in the late-stage TRIUMPH-4 trial.